0001193125-26-073379 Sample Contracts
REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • February 26th, 2026 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT, dated as of May 3, 2022 (this “Agreement”), is made and entered into by and among Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the entities set forth on Schedule 1.1 hereto (the “Initial Investors”) and any other entity or entities that become party hereto pursuant to Section 2.1(b)(ii) or Section 2.1(c) (together with the Initial Investors, the “Investors”, and each, individually, an “Investor”).
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 26th, 2026 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of February 25, 2026, is entered into by and among (a) PHATHOM PHARMACEUTICALS, INC., a Delaware corporation (“Phathom”), (b) each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (together with Phathom, individually or collectively, as the context may require, “Borrower”), (c) the several banks and other financial institutions or entities parties to this Amendment as “Existing Lenders” (collectively, referred to as the “Existing Lenders”), (d) the several banks and other financial institutions or entities parties to this Amendment as “New Lenders” (individually, a “New Lender”, and collectively, referred to as the “New Lenders”; together with the Existing Lenders, individually, a “Lender”, and collectively, referred to as the “Lenders”), and (e) HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for i